Patents Assigned to Xbiotech, Inc.
  • Modulation of the amount or function of pathogenic CD14+CD16+ monocytes
    Patent number: 8242074
    Abstract: The invention is based on the discovery that interleukin-1 alpha (IL-1alpha) is expressed on the proinflammatory CD14+CD16+ monocyte subset. Importantly, since IL-1alpha appears to be almost exclusively expressed on this monocyte subset and not other leukocytes, it represents an ideal marker for targeting the CD14+CD16+ monocyte subset. The effectiveness of an agent that depletes such pathogenic cells or modulates IL-1alpha function on such cells type can be monitored by assessing CD14+CD16+ monocyte levels or functionality.
    Type: Grant
    Filed: September 14, 2009
    Date of Patent: August 14, 2012
    Assignee: XBiotech, Inc.
    Inventor: John Simard
  • Interleukin-1 Alpha Antibodies and Methods of Use
    Publication number: 20120164665
    Abstract: Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1? and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.
    Type: Application
    Filed: September 2, 2011
    Publication date: June 28, 2012
    Applicant: XBIOTECH, INC.
    Inventor: John Simard
  • Diagnosis, treatment, and prevention of vascular disorders using IL-1 autoantibodies
    Patent number: 8187817
    Abstract: Methods of detecting individuals at risk for atherosclerosis and related vascular diseases involving the detection of IL-1? autoantibodies, as well as therapeutic methods to prevent or treat atherosclerosis and related vascular disease by administering a pharmaceutical composition comprising IL-1? autoantibodies.
    Type: Grant
    Filed: July 26, 2006
    Date of Patent: May 29, 2012
    Assignee: XBiotech, Inc.
    Inventors: John Simard, Klaus Bendtzen
  • IL-1alpha immunization induces autoantibodies protective against atherosclerosis
    Publication number: 20120114598
    Abstract: Immunization of a mammal with IL-1?, which causes the mammal to generate IL-1? autoantibodies, can be used to reduce the risk and severity of, or to reduce progression of, an atherosclerosis-related disease in the mammal. Progression of atherosclerosis-related diseases such as peripheral ischemic heart disease, coronary artery disease, cerebrovascular disease, and peripheral arterial disease can be reduced using this treatment.
    Type: Application
    Filed: January 9, 2012
    Publication date: May 10, 2012
    Applicant: XBIOTECH, INC.
    Inventor: John Simard
  • Characterizing an allotypic phenotype of a subject
    Publication number: 20120094301
    Abstract: Methods, compositions, and kits relating to selecting a prophylactic or therapeutic antibody less likely to induce or aggravate an anti-antibody response in a subject administered the antibody. An antibody for administration to a subject may be selected to match, or at least more closely resemble, the allotypic phenotype of the subject's endogenous antibodies.
    Type: Application
    Filed: December 2, 2011
    Publication date: April 19, 2012
    Applicant: XBIOTECH, INC.
    Inventor: John Simard
  • Methods for identifying a subject who has developed an anti-antibody response
    Publication number: 20120094395
    Abstract: Methods, compositions, and kits relating to selecting a prophylactic or therapeutic antibody less likely to induce or aggravate an anti-antibody response in a subject administered the antibody. An antibody for administration to a subject may be selected to match, or at least more closely resemble, the allotypic phenotype of the subject's endogenous antibodies.
    Type: Application
    Filed: December 2, 2011
    Publication date: April 19, 2012
    Applicant: XBIOTECH, INC.
    Inventor: John Simard
  • Treatment for Neoplastic Diseases
    Publication number: 20120045444
    Abstract: Administration of a mAb that specifically binds IL-1? is useful for treating tumor-associated diseases in human subjects.
    Type: Application
    Filed: August 23, 2011
    Publication date: February 23, 2012
    Applicant: XBIOTECH, INC.
    Inventor: John SIMARD
  • Interleukin-1 Alpha Antibodies and Methods of Use
    Publication number: 20120021512
    Abstract: Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1? and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.
    Type: Application
    Filed: September 2, 2011
    Publication date: January 26, 2012
    Applicant: XBIOTECH, INC.
    Inventor: John Simard
  • Interleukin-1 Alpha Antibodies and Methods of Use
    Publication number: 20120015384
    Abstract: Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1? and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.
    Type: Application
    Filed: September 2, 2011
    Publication date: January 19, 2012
    Applicant: XBIOTECH, INC.
    Inventor: John Simard
  • Interleukin-1 Alpha Antibodies and Methods of Use
    Publication number: 20120015433
    Abstract: Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1? and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.
    Type: Application
    Filed: September 2, 2011
    Publication date: January 19, 2012
    Applicant: XBIOTECH, INC.
    Inventor: John Simard
  • Interleukin-1 Alpha Antibodies and Methods of Use
    Publication number: 20120014971
    Abstract: Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1? and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.
    Type: Application
    Filed: September 2, 2011
    Publication date: January 19, 2012
    Applicant: XBIOTECH, INC.
    Inventor: John Simard
  • Arthritis Treatment
    Publication number: 20110311547
    Abstract: Administration of a monoclonal Ab (mAb) that specifically targets IL-1? is useful to treating articular and extra-articular symptoms of arthritis.
    Type: Application
    Filed: June 17, 2011
    Publication date: December 22, 2011
    Applicant: XBIOTECH, INC.
    Inventor: John Simard
  • Interleukin-1? antibodies
    Patent number: 8034337
    Abstract: Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1? and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.
    Type: Grant
    Filed: June 1, 2009
    Date of Patent: October 11, 2011
    Assignee: Xbiotech, Inc.
    Inventor: John Simard
  • Panel of monoclonal antibody containing pharmaceutical compositions
    Publication number: 20110071054
    Abstract: Methods, compositions, and kits relating to selecting a prophylactic or therapeutic antibody less likely to induce or aggravate an anti-antibody response in a subject administered the antibody. An antibody for administration to a subject may be selected to match, or at least more closely resemble, the allotypic phenotype of the subject's endogenous antibodies.
    Type: Application
    Filed: September 23, 2010
    Publication date: March 24, 2011
    Applicant: XBIOTECH, INC.
    Inventor: John Simard
  • Method of modifying a monoclonal antibody
    Publication number: 20110071276
    Abstract: Methods, compositions, and kits relating to selecting a prophylactic or therapeutic antibody less likely to induce or aggravate an anti-antibody response in a subject administered the antibody. An antibody for administration to a subject may be selected to match, or at least more closely resemble, the allotypic phenotype of the subject's endogenous antibodies.
    Type: Application
    Filed: September 23, 2010
    Publication date: March 24, 2011
    Applicant: XBIOTECH, INC.
    Inventor: John Simard
  • Method of selecting a monoclonal antibody for administration
    Publication number: 20110070229
    Abstract: Methods, compositions, and kits relating to selecting a prophylactic or therapeutic antibody less likely to induce or aggravate an anti-antibody response in a subject administered the antibody. An antibody for administration to a subject may be selected to match, or at least more closely resemble, the allotypic phenotype of the subject's endogenous antibodies.
    Type: Application
    Filed: September 23, 2010
    Publication date: March 24, 2011
    Applicant: XBIOTECH, INC.
    Inventor: John Simard
  • Method and devices for identifying and treating a subject who has developed an anti-antibody response
    Publication number: 20110070230
    Abstract: Methods, compositions, and kits relating to selecting a prophylactic or therapeutic antibody less likely to induce or aggravate an anti-antibody response in a subject administered the antibody. An antibody for administration to a subject may be selected to match, or at least more closely resemble, the allotypic phenotype of the subject's endogenous antibodies.
    Type: Application
    Filed: September 23, 2010
    Publication date: March 24, 2011
    Applicant: XBIOTECH, INC.
    Inventor: John Simard
  • IL-1alpha immunization induces autoantibodies protective against atherosclerosis
    Publication number: 20110008282
    Abstract: Immunization of a mammal with IL-1?, which causes the mammal to generate IL-1? autoantibodies, can be used to reduce the risk and severity of, or to reduce progression of, an atherosclerosis-related disease in the mammal. Progression of atherosclerosis-related diseases such as peripheral ischemic heart disease, coronary artery disease, cerebrovascular disease, and peripheral arterial disease can be reduced using this treatment.
    Type: Application
    Filed: September 22, 2010
    Publication date: January 13, 2011
    Applicant: XBIOTECH, INC.
    Inventor: John Simard
  • Targeting pathogenic monocytes
    Publication number: 20100068212
    Abstract: The invention is based on the discovery that interleukin-1 alpha (IL-1alpha) is expressed on the proinflammatory CD14+CD16+ monocyte subset. Importantly, since IL-1alpha appears to be almost exclusively expressed on this monocyte subset and not other leukocytes, it represents an ideal marker for targeting the CD14+CD16+ monocyte subset. The effectiveness of an agent that depletes such pathogenic cells or modulates IL-1alpha function on such cells type can be monitored by assessing CD14+CD16+ monocyte levels or functionality.
    Type: Application
    Filed: September 14, 2009
    Publication date: March 18, 2010
    Applicant: XBiotech, Inc.
    Inventor: John Simard
  • TREATMENT OF CANCER WITH ANTI-IL-1alpha ANTIBODIES
    Publication number: 20100040574
    Abstract: Treating a patient with anti-IL-1? antibody or anti-IL-1? immunization as a cancer treatment.
    Type: Application
    Filed: May 22, 2007
    Publication date: February 18, 2010
    Applicant: XBIOTECH INC.
    Inventor: John Simard